frexalimab
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Dec 7, 2023 (NCT06141486)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095122 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06500702 | Phase 2 | Aug 22, 2024 | Sanofi |
| NCT06141473 | Phase 3 | Dec 13, 2023 | Sanofi |
| NCT06111586 | Phase 2 | Dec 11, 2023 | Sanofi |
| NCT06141486 | Phase 3 | Dec 7, 2023 | Sanofi |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 4 | 4 | 2 | 2023 |
1 organizations
Page 1 / 1